Ulrich Sigwart: Difference between revisions
Philafrenzy (talk | contribs) |
ref |
||
Line 50: | Line 50: | ||
==Later career== |
==Later career== |
||
In 1987, after several years of preliminary work in animals, he published a landmark paper on the use intravascular [[stents]] in humans to prevent occlusion and re-stenosis after [[angioplasty]] of coronary and peripheral arteries.<ref name=Jiang2022>{{cite journal |last1=Jiang |first1=Wei |last2=Zhao |first2=Wenxiang |last3=Zhou |first3=Tianfeng |last4=Wang |first4=Liang |last5=Qiu |first5=Tianyang |title=A Review on Manufacturing and Post-Processing Technology of Vascular Stents |journal=Micromachines |date=16 January 2022 |volume=13 |issue=1 |pages=140 |doi=10.3390/mi13010140 |pmid=35056305 |url=https://pubmed.ncbi.nlm.nih.gov/35056305/ |language=en |issn=2072-666X}}</ref><ref> |
In 1987, after several years of preliminary work in animals, he published a landmark paper on the use intravascular [[stents]] in humans to prevent occlusion and re-stenosis after [[angioplasty]] of coronary and peripheral arteries.<ref name=Jiang2022>{{cite journal |last1=Jiang |first1=Wei |last2=Zhao |first2=Wenxiang |last3=Zhou |first3=Tianfeng |last4=Wang |first4=Liang |last5=Qiu |first5=Tianyang |title=A Review on Manufacturing and Post-Processing Technology of Vascular Stents |journal=Micromachines |date=16 January 2022 |volume=13 |issue=1 |pages=140 |doi=10.3390/mi13010140 |pmid=35056305 |url=https://pubmed.ncbi.nlm.nih.gov/35056305/ |language=en |issn=2072-666X}}</ref><ref name=Barton2014>{{cite journal |last1=Barton |first1=Matthias |last2=Grüntzig |first2=Johannes |last3=Husmann |first3=Marc |last4=Rösch |first4=Josef |title=Balloon Angioplasty – The Legacy of Andreas Grüntzig, M.D. (1939–1985) |journal=Frontiers in Cardiovascular Medicine |date=29 December 2014 |volume=1 |pages=15 |doi=10.3389/fcvm.2014.00015 |pmid=26664865 |url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4671350/ |issn=2297-055X}}</ref><ref>http://eurheartj.oxfordjournals.org/content/30/14/1677.full Pioneers in Cardiology]</ref> In 1994 he introduced percutaneous [[alcohol septal ablation]], a non-surgical method for the treatment of [[hypertrophic obstructive cardiomyopathy]], as an alternative to open heart surgery.<ref name=Thomas2005/><ref>Sigwart U: Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 1995;346:211–214</ref> During the years 1974–1978 he created the basis for the automated analysis of hemodynamic data and studied the repercussions of [[myocardial ischemia]]<ref>Sigwart U, Grbic M, Payot M, Goy J-J, Essinger A, et al.: Ischemic events during coronary artery balloon occlusion. In: Rutishauser |
||
W, Roskamm H, eds. Silent Myocardial Ischemia. Berlin: SpringerVerlag; 1984; 29–36</ref> and the performance of artificial heart valves. |
W, Roskamm H, eds. Silent Myocardial Ischemia. Berlin: SpringerVerlag; 1984; 29–36</ref> and the performance of artificial heart valves. |
||
Revision as of 09:45, 23 October 2022
![]() | This article or section is in a state of significant expansion or restructuring. You are welcome to assist in its construction by editing it as well. If this article or section has not been edited in several days, please remove this template. If you are the editor who added this template and you are actively editing, please be sure to replace this template with {{in use}} during the active editing session. Click on the link for template parameters to use.
This article was last edited by Whispyhistory (talk | contribs) 19 months ago. (Update timer) |
Ulrich Sigwart | |
---|---|
Born | 9 March 1941 |
Education | |
Known for |
|
Medical career | |
Institutions |
Ulrich Sigwart (German: [ˈziːkvaʁt]; born 9 March 1941) is a retired cardiologist known for his pioneering role in the conception and clinical use of vascular stents, and introducing a non-surgical intervention, alcohol septal ablation for the treatment of hypertrophic obstructive cardiomyopathy.
Early life and education
Ulrich Sigwart was born in Germany on 9 March 1941, the fifth child of August R. Sigwart, a Bayer Industries scientist, and his wife Elizabeth.[1] He was an infant when his father died under mysterious circumstances in Nazi-occupied Europe.[1] His family has its origins in Tübingen where several members played an important role at the local university.[1] Most of his ancestors were doctors, philosophers, or theologians, and a street in Tübingen is named after one of them.[1] He was subsequently raised by his mother and older siblings.[1]
In 1967 Sigwart received his medical degree from the University of Münster before gaining his MD that same year from the University of Freiburg.[2] His internship was completed in a hospital in Lörrach, Switzerland, between 1967 and 1968.[2][3]
Early career
Sigwart subsequently moved to the US and completed a residency at Framingham Union Hospital, Framingham, Massachusetts, between 1968–1971.[2] Between 1971 and 1972 he completed a Fellowship in cardiology at Baylor College of Medicine, Houston, and then completed cardiology training at the University Hospital of Zürich in 1973.[2][4]
Subsequently he was charged in 1973 to set up an invasive cardiology program at the Gollwitzer-Meier Institute in Bad Oeynhausen in Germany, which became the nidus for the Heart and Diabetes Center North Rhine-Westphalia. From 1979 to 1989 he headed the section of invasive cardiology at the Lausanne University Hospital in Switzerland.[citation needed]
Later career
In 1987, after several years of preliminary work in animals, he published a landmark paper on the use intravascular stents in humans to prevent occlusion and re-stenosis after angioplasty of coronary and peripheral arteries.[5][6][7] In 1994 he introduced percutaneous alcohol septal ablation, a non-surgical method for the treatment of hypertrophic obstructive cardiomyopathy, as an alternative to open heart surgery.[3][8] During the years 1974–1978 he created the basis for the automated analysis of hemodynamic data and studied the repercussions of myocardial ischemia[9] and the performance of artificial heart valves.
Andreas Gruentzig had already recognized the problem of abrupt closure and restenosis after angioplasty. The need for a suitable form of intraluminal support in the hope of reducing or preventing this problem became obvious. Several investigators envisioned such devices during the first years of clinical application of angioplasty. Following reassuring animal work with self expanding mesh stents in Lausanne Sigwart reported the first human implants of such vascular scaffolds. These vascular stents, implanted in peripheral and coronary circulation, were multi-filament self-expanding, spring-like devices made of surgical steel. Sigwart's work made angioplasty predictable which significantly improved the outcome and offered a chance to overcome the problem of abrupt closure and recurrence.
Sigwart's early stenting work received great interest and many travelled to Lausanne to observe the technique in practice. In a 1987 paper entitled ‘Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty’, Sigwart et al. gave an interesting account of the clinical use of stents to prevent occlusion and restenosis. Sigwart's work also provided him with an opportunity to observe the outcomes and indeed the shortcomings resulting from stent therapy.
Very early after the launch of vascular stents Sigwart voiced caution regarding the purely mechanical support. One such case was that of a patient who, 3 months after implantation in the proximal left anterior descending artery, developed severe chest pain and angiography showed severe restenosis. Sigwart urged the surgeon to remove the stented segment and reported how ‘gazing at the massive tissue obstructing the stent lumen, the hypothesis of mechanical support for the prevention of restenosis looked like an illusion' and he suggested that a combination of mechanical and biologic factors would help to overcome the problem of recurrence.
In 1989, Sigwart took up the directorship of the Department of Invasive Cardiology at the Royal Brompton Hospital in London, England, and during his 12-year tenure at this post, he initiated the first randomized study aimed at comparing percutaneous coronary intervention employing stents with the relatively well-accepted coronary bypass surgery (SoS: Stents or Surgery).[10]
He retired in 2006.[2]
Awards
- European Society of Cardiology Grüntzig Award 1996,
- Doctor honoris causa of the University of Lausanne 1999,
- Werner Forssmann Prize 2001,
- Sven Effert Prize 2003,
- King Faisal International Prize for Medicine 2004,[11]
- Swiss Society of Cardiology Grüntzig Award 2006,
- Polzer Prize of the European Academy of Sciences and Arts 2007,
- American College of Cardiology Maseri-Florio International Award 2007
- American College of Cardiology Paul Dudley White Award 2012
- American College of Cardiology Distinguished Scientist Award 2013
Selected publications
Articles
- Sigwart, U.; Puel, J.; Mirkovitch, V.; Joffre, F.; Kappenberger, L. (19 March 1987). "Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty". The New England Journal of Medicine. 316 (12): 701–706. doi:10.1056/NEJM198703193161201. ISSN 0028-4793. PMID 2950322.
- Sigwart, U. (22 July 1995). "Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy". Lancet (London, England). 346 (8969): 211–214. doi:10.1016/s0140-6736(95)91267-3. ISSN 0140-6736. PMID 7616800.
- Sigwart, U.; Grbic, M.; Payot, M.; Goy, J.-J.; Essinger, A.; Fischer, A. (1984). "Ischemic Events During Coronary Artery Balloon Obstruction". Silent Myocardial Ischemia. Springer: 29–36. doi:10.1007/978-3-642-69589-6_6.
Books
- U. Sigwart Automation in Cardiac Diagnosis: The Computer-Assisted Acquisition of Cardiac Catheterization Data, Schwabe 1978,
- U. Sigwart and P. H. Heintzen (Editors): Ventricular Wall Motion, Thieme 1984,
- U. Sigwart and G. I. Frank (Editors): Coronary Stents, Springer 1992 (ISBN 9780387545417) (Coronary Stents)
- U. Sigwart: Endoluminal Stenting, W. B. Saunders 1996 (ISBN 9780702020469) (Endoluminal Stenting)
- Ulrich Sigwart, Michel Bertrand, Patrick W. Serruys (Editors): Handbook on Cardiovascular Interventions, Churchill Livingstone, 1996
References
- ^ a b c d e King, Spencer B. (June 2008). "Ulrich Sigwart". Clinical Cardiology. 31 (6): 281–282. doi:10.1002/clc.20322.
- ^ a b c d e "Ulrich Sigwart". Cardiovascular News. BIBA Medical. 22 November 2011. Archived from the original on 23 October 2022. Retrieved 23 October 2022.
- ^ a b Puel, J. (2005). "Ulrich Sigwart". In Thomas, Adrian M. K.; Banerjee, Arpan K.; Busch, Uwe (eds.). Classic Papers in Modern Diagnostic Radiology. Springer. p. 531. ISBN 3-540-21927-7.
- ^ Mark, Allyn (2020). "6. Pioneers of coronary stenting". Pioneers Who Transformed Coronary Disease: From Eisenhower’s Heart Attack to Clinton’s Coronary Surgery and Stents. Bloomington: AuthorHouse. p. 127. ISBN 978-1-7283-6959-4.
- ^ Jiang, Wei; Zhao, Wenxiang; Zhou, Tianfeng; Wang, Liang; Qiu, Tianyang (16 January 2022). "A Review on Manufacturing and Post-Processing Technology of Vascular Stents". Micromachines. 13 (1): 140. doi:10.3390/mi13010140. ISSN 2072-666X. PMID 35056305.
{{cite journal}}
: CS1 maint: unflagged free DOI (link) - ^ Barton, Matthias; Grüntzig, Johannes; Husmann, Marc; Rösch, Josef (29 December 2014). "Balloon Angioplasty – The Legacy of Andreas Grüntzig, M.D. (1939–1985)". Frontiers in Cardiovascular Medicine. 1: 15. doi:10.3389/fcvm.2014.00015. ISSN 2297-055X. PMID 26664865.
{{cite journal}}
: CS1 maint: unflagged free DOI (link) - ^ http://eurheartj.oxfordjournals.org/content/30/14/1677.full Pioneers in Cardiology]
- ^ Sigwart U: Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 1995;346:211–214
- ^ Sigwart U, Grbic M, Payot M, Goy J-J, Essinger A, et al.: Ischemic events during coronary artery balloon occlusion. In: Rutishauser W, Roskamm H, eds. Silent Myocardial Ischemia. Berlin: SpringerVerlag; 1984; 29–36
- ^ The SoS Investigators: Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery trial): a randomised controlled trial. Lancet 2002;360:965–970
- ^ King Faisal International Prize 2004